Logo Logo

Category Archives: "INforMS"

  1. Home
  2. INforMS
  3. Page 32
Oct 20, 2014
Results from two phase III studies added to U.S. label of Genzyme’s Aubagio
INforMS, Partners
Results from Two Phase III Studies Added to U.S. Label of Genzyme’s Aubagio Once-daily Aubagio is the only oral treatment to [...]
Elizabeth Porco
Read More
...21
0
Sep 11, 2014
At four years, treatment effect maintained in patients who received Lemtrada in studies
INforMS, Partners
At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme’s Lemtrada in Pivotal Studies - In [...]
Elizabeth Porco
Read More
...22
0
Sep 10, 2014
New international survey finds multiple sclerosis patients and neurologists view communication positively
INforMS, MS Community, Partners
New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet Struggle to Discuss Key MS [...]
Elizabeth Porco
Read More
...21
0
Aug 15, 2014
Biogen Idec’s PLEGRIDY approved in the US for the treatment of multiple sclerosis
INforMS, Partners
Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis Friday, August 15, 2014 [...]
Elizabeth Porco
Read More
...26
0
Jul 23, 2014
PLEGRIDY (Peginterferon beta-1a) approved in the EU for the treatment of multiple sclerosis
INforMS, Partners
PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis Wednesday, July 23, 2014 [...]
Elizabeth Porco
Read More
...24
0
Jul 03, 2014
Teva files citizen petition with the US FDA regarding the complexity of COPAXONE
INforMS, Partners
Teva files Citizen Petition with the U.S. Food and Drug Administration (FDA) regarding the Complexity of COPAXONE® (Glatiramer Acetate) [...]
Elizabeth Porco
Read More
...24
0
Jun 30, 2014
Genzyme’s Lemtrada approved in Argentina for treatment of multiple sclerosis
INforMS, Partners
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis Monday, June 30, 2014 8:00 am EDT CAMBRIDGE, [...]
Elizabeth Porco
Read More
...26
0
Jun 16, 2014
Biogen Idec and AbbVie Announce Results from Phase 3 Study Investigating Daclizumab
INforMS, Partners
Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple [...]
Elizabeth Porco
Read More
...21
0
May 30, 2014
Genzyme’s Lemtrada resubmission accepted for review by FDA
INforMS, Partners
Genzyme’s Lemtrada Resubmission Accepted for Review by FDA - Agency action expected in Q4 2014 - Cambridge, Mass. - May 30, 2014 - [...]
Elizabeth Porco
Read More
...27
0
May 30, 2014
Data from Biogen Idec’s portfolio of multiple sclerosis therapies and pipeline featured at congresses
INforMS, Partners
Data from Biogen Idec’s Portfolio of Multiple Sclerosis Therapies and Pipeline Featured at Medical Congresses Friday, May 30, 2014 [...]
Elizabeth Porco
Read More
...23
0
  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us
I have a question about
First
Last

Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM